Chronomodulated capecitabine in combination with short-time oxaliplatin: A Nordic phase II study of second-line therapy in patients with metastatic colorectal cancer after failure to irinotecan and 5-flourouracil

Qvortrup, C.Department of Oncology, Odense University Hospital, Sdr. Boulevard 29, Odense C 5000, Denmark, Institute of Clinical Research, University of Southern Denmark, Odense, Denmark (författare)

Chronomodulated capecitabine in combination with short-time oxaliplatin : A Nordic phase II study of second-line therapy in patients with metastatic colorectal cancer after failure to irinotecan and 5-flourouracil

Background: Oxaliplatin in combination with capecitabine prolongs survival in patients with metastatic colorectal cancer (mCRC). Chronomodulation might reduce toxicity and improve efficacy. Patients and methods: A phase II study examining chronomodulated XELOX30 (XELOX30chron): oxaliplatin: 130 mg/m2 on day 1, as a 30-min infusion between 1 and 3 p.m. Capecitabine: total daily dose of 2000 mg/m2, 20% of the dose between 7 and 9 a.m. and 80% of the dose between 6 and 8 p.m. in patients with mCRC resistant to irinotecan. Seventy-one patients were enrolled. Response rate was 18%, median progression-free survival 5.1 months and median overall survival (OS) 10.2 months. Platelet count and performance status were significantly correlated to OS in multivariate analyses. Neurotoxicity grade 2 and 3 was seen in 25% and 2% of patients, respectively, other grade 3 toxic effects were as follows: nausea 6%, vomiting 3%, diarrhoea 12% (3% experienced grade 4) and palmoplantart erytem 9%. Conclusion: XELOX30chron is a convenient second-line regimen with efficacy and safety profile similar to other oxaliplatin schedules. To further investigate chronomodulated XELOX, we have started a Nordic randomised phase II study comparing XELOX30 and XELOX30chron as first-line therapy in patients with mCRC. © The Author 2008. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved.

Yilmaz, M.Department of Oncology, Aalborg University Hospital, Aalborg, Denmark (författare)
Ogreid, D.Department of Oncology, Rogaland Central Hospital, Stavanger, Norway (författare)
Berglund, ÅkeUppsala universitet,Enheten för onkologi,Ake Berglund(Swepub:uu)akebergl (författare)
Balteskard, L.Department of Oncology, Tromso University Hospital, Tromso, Norway (författare)
Ploen, J.Department of Oncology, Vejle Hospital, Vejle, Denmark (författare)
Fokstuen, T.Department of Oncology and Pathology, Karolinska Hospital, Stockholm, Sweden (författare)
Starkhammar, HansÖstergötlands Läns Landsting,Linköpings universitet,Onkologi,Hälsouniversitetet,Onkologiska kliniken US(Swepub:liu)hanst87 (författare)
Sorbye, H.Sørbye, H., Department of Oncology, Haukeland University Hospital, Bergen, Norway (författare)
Tveit, K.Department of Oncology, Ullevål University Hospital, Oslo, Norway (författare)
Pfeiffer, P.Department of Oncology, Odense University Hospital, Sdr. Boulevard 29, Odense C 5000, Denmark (författare)
Department of Oncology, Odense University Hospital, Sdr. Boulevard 29, Odense C 5000, Denmark, Institute of Clinical Research, University of Southern Denmark, Odense, DenmarkDepartment of Oncology, Aalborg University Hospital, Aalborg, Denmark (creator_code:org_t)

Av författaren/redakt...: Qvortrup, C.; Yilmaz, M.; Ogreid, D.; Berglund, Åke; Balteskard, L.; Ploen, J.; visa fler...; Fokstuen, T.; Starkhammar, Han ...; Sorbye, H.; Tveit, K.; Pfeiffer, P.; visa färre...

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.